-
09:08:07 PM

GH Stock News

12/01/22 8:05 AM
Nasdaq : GH
Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients
Guardant Health, Inc., a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas. “We look forward to sharing new data at the San Antonio Breast Cancer Symposium demonstrating the utility of our blood tests to increase...
RHEA-AI
neutral
09/09/22 4:30 PM
Nasdaq : GH
Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner
Guardant Health, Inc., a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development. “Realizing the promise of precision...
RHEA-AI
neutral
09/06/22 8:05 AM
Nasdaq : GH
Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients
Guardant Health, Inc., a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 European Society for Medical Oncology Congress, September 9-13 in Paris, France. “We look forward to sharing new data at ESMO demonstrating the utility of our blood tests to increase the understanding of...
RHEA-AI
neutral
08/31/22 8:05 AM
Nasdaq : GH
Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics
Guardant Health, Inc., a leading precision oncology company, today announced an expanded collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating its biopharmaceuticals business in the U.S. and Canada as EMD Serono, to further leverage the GuardantINFORM real-world evidence platform to help accelerate...
RHEA-AI
very positive
08/15/22 8:05 AM
Nasdaq : GH
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
Guardant Health Inc., a leading precision oncology company, announced today that Guardant Reveal™, the only tissue-free test for the detection of residual and recurrent disease for colorectal cancer, is now available for patients with breast and lung cancers. “We are very pleased to be able to make the Guardant Reveal test available to patients with breast and...
RHEA-AI
neutral
08/12/22 8:05 AM
Nasdaq : GH
fda approval
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations
Guardant Health, Inc., a leading precision oncology company, announced today that the U.S. Food and Drug Administration has approved its Guardant360 ® CDx liquid biopsy test as a companion diagnostic to select patients with unresectable or metastatic HER2- mutant non-small cell lung cancer whose tumors have activating HER2 mutations for treatment with...
RHEA-AI
very positive
08/08/22 4:05 PM
Nasdaq : GH
conferences
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference
Guardant Health, Inc., a leading precision oncology company, today announced it will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit Conference in Dana Point, CA.. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and...
RHEA-AI
neutral